Does Alzheimer's disease with early onset progress faster than with late onset? A case-control study of clinical progression and cerebrospinal fluid biomarkers

Dementia and Geriatric Cognitive Disorders

Volumn 33, Issue 2-3, 2012, Pages 111-117

  Gronning H ^a,c   Rahmani, A ^a   Gyllenborg, J ^a   Dessau, R B ^b   Hogh P ^a  

^a Mental Health Center Glostrup   (Denmark)

^b SLAGELSE HOSPITAL   (Denmark)

^c ROSKILDE HOSPITAL   (Denmark)

Author keywords

Cerebrospinal fluid biomarkers; Disease progression; Early onset Alzheimer's disease; Late onset Alzheimer's disease

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; EARLY ONSET ALZHEIMER DISEASE; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; MALE; PRIORITY JOURNAL; SCORING SYSTEM;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DENMARK; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INTELLIGENCE TESTS; MALE; MEMORY DISORDERS; MENTAL COMPETENCY; MIDDLE AGED; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; REGISTRIES;

EID: 84859630633     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000337386     Document Type: Article

References (36)

1. Goldman JS, Hou CE: Early-onset Alzheimer disease: When is genetic testing appropriate? Alzheimer Dis Assoc Disord 2004; 18: 65-67.
2. Balasa M, Gelpi E, Antonell A, Rey MJ, Sanchez-Valle R, Molinuevo JL, et al: Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 2011; 76: 1720-1725.
3. Phung TK, Andersen BB, Høgh P, Kessing LV, Mortensen PB, Waldemar G: Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord 2007; 24: 220-228.
4. Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA: Early-versus late-onset Alzheimer's disease: More than age alone. J Alzheimers Dis 2010; 19: 1401-1408.
5. Fujimori M, Imamura T, Yamashita H, Hirono N, Ikejiri Y, Shimomura T, et al: Age at onset and visuocognitive disturbances in Alz heimer disease. Alzheimer Dis Assoc Disord 1998; 12: 163-166.
6. Imamura T, Takatsuki Y, Fujimori M, Hirono N, Ikejiri Y, Shimomura T, et al: Age at onset and language disturbances in Alzheimer's disease. Neuropsychologia 1998; 36: 945-949.
7. Suribhatla S, Baillon S, Dennis M, Marudkar M, Muhammad S, Munro D, et al: Neuropsychological performance in early and late onset Alzheimer's disease: Comparisons in a memory clinic population. Int J Geriatr Psychiatry 2004; 19: 1140-1147.
8. Høgh P, Sjø NM, Gade A, Waldemar G: Temporal lobe hypoperfusion in isolated amnesia with slow onset: A SPECT study. Dementia Geriatr Cogn Disord 2004; 18: 15-23.
9. Apostolova LG, Hwang KS, Medina LD, Green AE, Braskie MN, Dutton RA, Lai J, Geschwind DH, Cummings JL, Thompson PM, Ringman JM: Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease. Dement Geriatr Cogn Disord 2011; 32: 118-125.
10. Baumann TP, Duyar H, Sollberger M, Kuhle J, Regeniter A, Gomez-Mancilla B, Schmidtke K, Monsch AU: CSF-tau and CSF-Abeta( 1-42) in posterior cortical atrophy. Dement Geriatr Cogn Disord 2010; 29: 530-533.
11. Koric L, Felician O, Guedj E, Hubert AM, Mancini J, Boucraut J, et al: Could clinical profile influence CSF biomarkers in earlyonset Alzheimer disease? Alzheimer Dis Assoc Disord 2010; 24: 278-283.
12. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, et al: Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009; 66: 638-645.
13. Wahlund LO, Blennow K: Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003; 339: 99-102.
14. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O: CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010; 74: 1531-1537.
15. Stokholm J, Vogel A, Johannsen P, Waldemar G: Validation of the Danish Addenbrooke's Cognitive Examination as a screening test in a memory clinic. Dement Geriatr Cogn Disord 2009; 27: 361-365.
16. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S33-S39.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
18. Brandt C, Bahl JC, Heegaard NH, Waldemar G, Johannsen P: Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic. Dement Geriatr Cogn Disord 2008; 25: 553-558.
19. Ho GJ, Hansen LA, Alford MF, Foster K, Salmon DP, Galasko D, et al: Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. Neuroreport 2002; 13: 1825-1828.
20. van der Vlies AE, Koedam EL, Pijnenburg YA, Twisk JW, Scheltens P, van der Flier WM: Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset. Psychol Med 2009; 39: 1907-1911.
21. Lucca U, Comelli M, Tettamanti M, Tiraboschi P, Spagnoli A: Rate of progression and prognostic factors in Alzheimer's disease: A prospective study. J Am Geriatr Soc 1993; 41: 45-49.
22. Jacobs D, Sano M, Marder K, Bell K, Bylsma F, Lafleche G, et al: Age at onset of Alzheimer's disease: Relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994; 44: 1215-1220.
23. Wilson RS, Gilley DW, Bennett DA, Beckett LA, Evans DA: Person-specific paths of cognitive decline in Alzheimer's disease and their relation to age. Psychol Aging 2000; 15: 18-28.
24. Katzman R, Brown T, Thal LJ, Fuld PA, Aronson M, Butters N, et al: Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer's disease. Ann Neurol 1988; 24: 384-389.
25. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M: Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord 2009; 27: 458-464.
26. Wallin A, Göthlin M, Gustavsson M, Zetterberg H, Eckerström C, Blennow K, Edman A, Lind K, Nordlund A, Rolstad S: Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations. Dement Geriatr Cogn Disord 2011; 32: 193-197.
27. Behl P, Stefurak TL, Black SE: Progress in clinical neurosciences: Cognitive markers of progression in Alzheimer's disease. Can J Neurol Sci 2005; 32: 140-151.
28. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, et al: Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: A clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1999; 56: 857-862.
29. Koepsell TD, Kurland BF, Harel O, Johnson EA, Zhou XH, Kukull WA: Education, cognitive function, and severity of neuropathology in Alzheimer disease. Neurology 2008; 70: 1732-1739.
30. Hall CB, Derby C, LeValley A, Katz MJ, Verghese J, Lipton RB: Education delays accelerated decline on a memory test in persons who develop dementia. Neurology 2007; 69: 1657-1664.
31. Scarmeas N, Albert SM, Manly JJ, Stern Y: Education and rates of cognitive decline in incident Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006; 77: 308-316.
32. Storandt M, Grant EA, Miller JP, Morris JC: Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology 2002; 59: 1034-1041.
33. Bouwman FH, van der Flier WM, Schoonenboom NS, van Elk EJ, Kok A, Rijmen F, et al: Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007; 69: 1006-1011.
34. Thies W, Bleiler L: Alzheimer's disease facts and figures. Alzheimers Dement 2011; 7: 208-244.
35. Caroli A, Frisoni GB: The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging 2010; 31: 1263-1274.
36. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O: Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.